Amarin Corp. PLC (NASDAQ:AMRN) was up 3.1% during mid-day trading on Tuesday . The stock traded as high as $3.30 and last traded at $3.29, with a volume of 1,015,046 shares. The stock had previously closed at $3.19.

Several equities research analysts have recently issued reports on AMRN shares. Zacks Investment Research upgraded Amarin Corp. PLC from a “sell” rating to a “hold” rating in a report on Tuesday, April 26th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Amarin Corp. PLC in a report on Monday, May 9th. Finally, Jefferies Group started coverage on Amarin Corp. PLC in a report on Thursday, May 12th. They set a “buy” rating and a $3.50 price objective on the stock.

The stock’s market cap is $614.29 million. The firm’s 50-day moving average price is $2.39 and its 200 day moving average price is $1.85.

Amarin Corp. PLC (NASDAQ:AMRN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. During the same quarter last year, the company earned ($0.15) earnings per share. The firm earned $32.82 million during the quarter, compared to analyst estimates of $29.97 million. The business’s revenue for the quarter was up 85.4% on a year-over-year basis. On average, equities analysts forecast that Amarin Corp. PLC will post ($0.53) EPS for the current fiscal year.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.